宫颈癌的相关免疫治疗及进展

doi:10.12280/gjfckx.20210116

摘要/Abstract

摘要：

宫颈癌是最常见的妇科恶性肿瘤,严重威胁女性健康。高危型人乳头瘤病毒（human papillomavirus,HPV）持续感染是宫颈癌的主要危险因素。近年来,HPV疫苗在宫颈癌预防方面取得了良好的效果,免疫治疗也成为了宫颈癌治疗的新模式,尤其对于手术、放化疗效果不佳和术后转移及晚期复发的患者,免疫治疗尤为重要。免疫治疗的策略主要包括免疫检查点抑制剂、疫苗治疗、树突状细胞免疫疗法和过继细胞免疫疗法。目前,相关的免疫疗法在宫颈癌及其癌前病变治疗的研究中均取得了不错的疗效。综述宫颈癌中的免疫治疗进展,并对今后的研究方向做出展望,从而为宫颈癌的临床治疗和基础研究提供依据。

关键词: 宫颈肿瘤, 免疫疗法, 乳头状瘤病毒科, 乳头状瘤病毒疫苗, 治疗

Abstract:

Cervical cancer is the most common gynecological malignant tumor, which is a serious threat to women′s health. High-risk human papillomavirus (HPV) persistent infection is the main risk factor of the cervical cancer. In recent years, HPV vaccine has achieved favorable results in the prevention of cervical cancer. Immunotherapy has also become a new pattern of treatment of cervical cancer, especially for patients with poor effect of surgery, radiotherapy and chemotherapy, postoperative metastasis and late recurrence. The strategies of immunotherapy mainly include immune checkpoint inhibitors, vaccine therapy, dendritic cell immunotherapy and adoptive cellular immunotherapy. At present, the related immunotherapy has achieved good results in the treatment of cervical cancer and its precancerous lesions. This article will describe the progress of immunotherapy in cervical cancer, and look forward to the future research direction, so as to provide a basis for clinical treatment and fundamental research of cervical cancer.

Key words: Uterine cervical neoplasms, Immunotherapy, Papillomaviridae, Papillomavirus vaccines, Therapy

尹博, 丁鉴夷, 杨美琴, 韩凌斐. 宫颈癌的相关免疫治疗及进展[J]. 国际妇产科学杂志, 2021, 48(6): 628-633.

YIN Bo, DING Jian-yi, YANG Mei-qin, HAN Ling-fei. Related Immunotherapy and Progress of Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(6): 628-633.

参考文献 29

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019,69(1):7-34. doi: 10.3322/caac.21551. doi: 10.3322/caac.21551
[2]	Lee SJ, Yang A, Wu TC, et al. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research[J]. J Gynecol Oncol, 2016,27(5):e51. doi: 10.3802/jgo.2016.27.e51. doi: 10.3802/jgo.2016.27.e51
[3]	Chan CK, Aimagambetova G, Ukybassova T, et al. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives[J]. J Oncol, 2019,2019:3257939. doi: 10.1155/2019/3257939. doi: 10.1155/2019/3257939
[4]	Mühr L, Eklund C, Dillner J. Towards quality and order in human papillomavirus research[J]. Virology, 2018,519:74-76. doi: 10.1016/j.virol.2018.04.003. doi: 10.1016/j.virol.2018.04.003
[5]	Allouch S, Malki A, Allouch A, et al. High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions[J]. Front Oncol, 2020,10:914. doi: 10.3389/fonc.2020.00914. doi: 10.3389/fonc.2020.00914
[6]	Menéndez-Menéndez J, Hermida-Prado F, Granda-Díaz R, et al. Deciphering the Molecular Basis of Melatonin Protective Effects on Breast Cells Treated with Doxorubicin: TWIST1 a Transcription Factor Involved in EMT and Metastasis, a Novel Target of Melatonin[J]. Cancers (Basel), 2019,11(7) doi: 10.3390/cancers11071011. doi: 10.3390/cancers11071011
[7]	Li X, Wang R, Fan P, et al. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer[J]. Front Oncol, 2019,9:1066. doi: 10.3389/fonc.2019.01066. doi: 10.3389/fonc.2019.01066
[8]	Cheng MA, Farmer E, Huang C, et al. Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases[J]. Hum Gene Ther, 2018,29(9):971-996. doi: 10.1089/hum.2017.197. doi: 10.1089/hum.2017.197 pmid: 29316817
[9]	Menderes G, Black J, Schwab CL, et al. Immunotherapy and targeted therapy for cervical cancer: an update[J]. Expert Rev Anticancer The, 2016,16(1):83-98. doi: 10.1586/14737140.2016.1121108. doi: 10.1586/14737140.2016.1121108
[10]	Chabeda A, Yanez R, Lamprecht R, et al. Therapeutic vaccines for high-risk HPV-associated diseases[J]. Papillomavirus Res, 2018,5:46-58. doi: 10.1016/j.pvr.2017.12.006. doi: S2405-8521(17)30057-5 pmid: 29277575
[11]	Vonsky M, Shabaeva M, Runov A, et al. Carcinogenesis Associated with Human Papillomavirus Infection. Mechanisms and Potential for Immunotherapy[J]. Biochemistry (Mosc), 2019,84(7):782-799. doi: 10.1134/S0006297919070095. doi: 10.1134/S0006297919070095
[12]	Peter M, Kühnel F. Oncolytic Adenovirus in Cancer Immunotherapy[J]. Cancers (Basel), 2020,12(11):3354. doi: 10.3390/cancers12113354. doi: 10.3390/cancers12113354
[13]	Hasan Y, Furtado L, Tergas A, et al. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer[J]. Int J Radiat Oncol Biol Phys, 2020,107(3):487-498. doi: 10.1016/j.ijrobp.2020.02.031. doi: 10.1016/j.ijrobp.2020.02.031
[14]	Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors[J]. Cochrane Database Syst Rev, 2018,5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3. doi: 10.1002/14651858.CD009069.pub3
[15]	Østergård S, Vorbeck CS, Meinert M. Vulvar intraepithelial neoplasia[J]. Ugeskr Laeger, 2018,180(20):V12170931.
[16]	Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients[J]. Nat Commun, 2014,5:5317. doi: 10.1038/ncomms6317. doi: 10.1038/ncomms6317
[17]	Çuburu N, Khan S, Thompson CD, et al. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins[J]. Int J Cancer, 2018,142(7):1467-1479. doi: 10.1002/ijc.31166. doi: 10.1002/ijc.31166
[18]	Kim TW, Hung CF, Juang J, et al. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death[J]. Gene Ther, 2004,11(3):336-342. doi: 10.1038/sj.gt.3302164. doi: 10.1038/sj.gt.3302164 pmid: 14737094
[19]	Fakhr E, Modic Ž, Cid-Arregui A. Recent developments in immunotherapy of cancers caused by human papillomaviruses[J]. Immunology, 2021,163(1):33-45. doi: 10.1111/imm.13285. doi: 10.1111/imm.13285
[20]	Schetters S, Jong W, Horrevorts SK, et al. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8(+) T cells[J]. Acta Biomater, 2019,91:248-257. doi: 10.1016/j.actbio.2019.04.033. doi: S1742-7061(19)30276-4 pmid: 31003032
[21]	Santin AD, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities[J]. Gynecol Oncol, 2006,100(3):469-478. doi: 10.1016/j.ygyno.2005.09.040. doi: 10.1016/j.ygyno.2005.09.040
[22]	Aipire A, Li J, Yuan P, et al. Glycyrrhiza uralensis water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine[J]. Sci Rep, 2017,7:43796. doi: 10.1038/srep43796. doi: 10.1038/srep43796 pmid: 28272545
[23]	Zsiros E, Tsuji T, Odunsi K. Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer[J]. J Clin Oncol, 2015,33(14):1521-1522. doi: 10.1200/JCO.2014.60.6566. doi: 10.1200/JCO.2014.60.6566 pmid: 25847926
[24]	Jin BY, Campbell TE, Draper LM, et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model[J]. JCI Insight, 2018,3(8):e99488. doi: 10.1172/jci.insight.99488. doi: 10.1172/jci.insight.99488
[25]	Singh N, Shi J, June CH, et al. Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer[J]. Curr Hematol Malig Rep, 2017,12(6):522-529. doi: 10.1007/s11899-017-0417-7. doi: 10.1007/s11899-017-0417-7
[26]	Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine[J]. Nat Rev Immunol, 2020,20(5):321-334. doi: 10.1038/s41577-019-0269-6. doi: 10.1038/s41577-019-0269-6
[27]	Zhuo M, Chi Y, Wang Z. The adverse events associated with combination immunotherapy in cancers: Challenges and chances[J]. Asia Pac J Clin Oncol, 2020,16(5):e154-e159. doi: 10.1111/ajco.13365. doi: 10.1111/ajco.13365
[28]	Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy[J]. Nat Commun, 2019,10(1):5408. doi: 10.1038/s41467-019-13368-y. doi: 10.1038/s41467-019-13368-y
[29]	Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy[J]. Cancer Lett, 2020,470:126-133. doi: 10.1016/j.canlet.2019.11.009. doi: S0304-3835(19)30564-6 pmid: 31730903